These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 23297134

  • 1. Robust T-cell stimulation by Epstein-Barr virus-transformed B cells after antigen targeting to DEC-205.
    Leung CS, Maurer MA, Meixlsperger S, Lippmann A, Cheong C, Zuo J, Haigh TA, Taylor GS, Münz C.
    Blood; 2013 Feb 28; 121(9):1584-94. PubMed ID: 23297134
    [Abstract] [Full Text] [Related]

  • 2. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.
    Gurer C, Strowig T, Brilot F, Pack M, Trumpfheller C, Arrey F, Park CG, Steinman RM, Münz C.
    Blood; 2008 Aug 15; 112(4):1231-9. PubMed ID: 18519810
    [Abstract] [Full Text] [Related]

  • 3. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
    Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, Schuler G, Schaft N, Dörrie J.
    Blood; 2010 Sep 30; 116(13):2277-85. PubMed ID: 20566893
    [Abstract] [Full Text] [Related]

  • 4. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
    Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM.
    J Exp Med; 2000 May 15; 191(10):1649-60. PubMed ID: 10811859
    [Abstract] [Full Text] [Related]

  • 5. Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
    Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Münz C.
    J Exp Med; 2001 Feb 05; 193(3):405-11. PubMed ID: 11157061
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
    Subklewe M, Sebelin K, Block A, Meier A, Roukens A, Paludan C, Fonteneau JF, Steinman RM, Münz C.
    Hum Immunol; 2005 Sep 05; 66(9):938-49. PubMed ID: 16360833
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.
    Tsuji T, Matsuzaki J, Kelly MP, Ramakrishna V, Vitale L, He LZ, Keler T, Odunsi K, Old LJ, Ritter G, Gnjatic S.
    J Immunol; 2011 Jan 15; 186(2):1218-27. PubMed ID: 21149605
    [Abstract] [Full Text] [Related]

  • 12. Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.
    Grossmann C, Tenbusch M, Nchinda G, Temchura V, Nabi G, Stone GW, Kornbluth RS, Uberla K.
    BMC Immunol; 2009 Aug 03; 10():43. PubMed ID: 19650904
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G.
    Egypt J Immunol; 2008 Aug 03; 15(1):145-57. PubMed ID: 20306679
    [Abstract] [Full Text] [Related]

  • 14. CD4+ T-cell clones recognizing human lymphoma-associated antigens: generation by in vitro stimulation with autologous Epstein-Barr virus-transformed B cells.
    Long HM, Zuo J, Leese AM, Gudgeon NH, Jia H, Taylor GS, Rickinson AB.
    Blood; 2009 Jul 23; 114(4):807-15. PubMed ID: 19443664
    [Abstract] [Full Text] [Related]

  • 15. Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo.
    Volckmar J, Knop L, Hirsch T, Frentzel S, Erck C, van Ham M, Stegemann-Koniszewski S, Bruder D.
    J Vis Exp; 2021 Feb 05; (168):. PubMed ID: 33616089
    [Abstract] [Full Text] [Related]

  • 16. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells.
    Adams EW, Ratner DM, Seeberger PH, Hacohen N.
    Chembiochem; 2008 Jan 25; 9(2):294-303. PubMed ID: 18186095
    [Abstract] [Full Text] [Related]

  • 17. Primary immune responses by cord blood CD4(+) T cells and NK cells inhibit Epstein-Barr virus B-cell transformation in vitro.
    Wilson AD, Morgan AJ.
    J Virol; 2002 May 25; 76(10):5071-81. PubMed ID: 11967323
    [Abstract] [Full Text] [Related]

  • 18. Human dendritic cells pulsed with autologous Epstein-Barr virus transformed B-cell lymphoblastoid cell (BCL) lysate elicit a BCL specific MHC-class II restricted T-cell response.
    Sugano M, Conway TF, Kelleher RJ, Sugiyama Y, Chen FA, Bankert RB, Bernstein SH.
    J Exp Clin Cancer Res; 2001 Jun 25; 20(2):175-82. PubMed ID: 11484971
    [Abstract] [Full Text] [Related]

  • 19. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
    Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM.
    Ann N Y Acad Sci; 2009 Sep 25; 1174():6-17. PubMed ID: 19769731
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of melanoma growth by targeting of antigen to dendritic cells via an anti-DEC-205 single-chain fragment variable molecule.
    Johnson TS, Mahnke K, Storn V, Schönfeld K, Ring S, Nettelbeck DM, Haisma HJ, Le Gall F, Kontermann RE, Enk AH.
    Clin Cancer Res; 2008 Dec 15; 14(24):8169-77. PubMed ID: 19088032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.